Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis
IntroductionThis meta-analysis aimed to evaluate the efficacy and safety of Lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors (PD-1 inhibitors) in the treatment of intermediate or advanced hepatocellular carcinoma (HCC).Materials and MethodsFour databases...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1586914/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850073771435622400 |
|---|---|
| author | Yongfa Lei Xiaotian Liang Hua Zhu Jin Wang Xiaochen Zhang Xiaochen Zhang Siliang Duan Siliang Duan Weiming Liang |
| author_facet | Yongfa Lei Xiaotian Liang Hua Zhu Jin Wang Xiaochen Zhang Xiaochen Zhang Siliang Duan Siliang Duan Weiming Liang |
| author_sort | Yongfa Lei |
| collection | DOAJ |
| description | IntroductionThis meta-analysis aimed to evaluate the efficacy and safety of Lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors (PD-1 inhibitors) in the treatment of intermediate or advanced hepatocellular carcinoma (HCC).Materials and MethodsFour databases (Pubmed, Embase, Web of Science, and Cochrane Library) were searched for studies comparing lenvatinib plus transarterial chemoembolization with PD-1 inhibitors (TACE-L-P) versus Lenvatinib plus transarterial chemoembolization (TACE-L) for intermediate or advanced HCC. Meta-analyses were conducted for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and Grade ≥ 3 treatment-related adverse events (Grade ≥ 3 AEs).ResultsThe meta-analysis comprised 19 retrospective cohort studies, including of 2002 patients diagnosed with intermediate or advanced HCC. In this cohort, 1011 individuals were administered TACE-L-P, while 991 patients received TACE-L. In comparison to TACE-L, TACE-L-P demonstrated a superior ORR [odds ratio (OR) = 2.38, 95% confidence interval (CI) 1.98 ~ 2.87, P < 0.00001] and DCR (OR = 3.22, 95% CI, 2.32 ~ 4.45, P < 0.00001). TACE-L-P showed superior efficacy compared to TACE-L regarding PFS (HR: 0.56, 95%CI 0.50 to 0.62, P<0.0001) and OS (HR: 0.70, 95%CI 0.60 to 0.80, P<0.0001). Regarding safety, the incidence of Grade ≥ 3 AEs was more prevalent in the TACE-L-P group compared to the TACE-L group (OR=1.58, 95% CI: 1.27 ~ 1.97, P<0.0001).ConclusionsThe present meta-analysis present a comparison of the efficacy and safety of TACE-L-P against TACE-L for intermediate or advanced HCC. TACE-L-P enhanced ORR, DCR, PFS, and OS relative to TACE-L. Furthermore, the improved efficacy of TACE-L-P was correlated with a rise in the incidence of Grade ≥ 3 AEs.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024590414, identifier CRD42024590414. |
| format | Article |
| id | doaj-art-2cf9691d5bd4477a88d8f614f5fb5823 |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-2cf9691d5bd4477a88d8f614f5fb58232025-08-20T02:46:44ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.15869141586914Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysisYongfa Lei0Xiaotian Liang1Hua Zhu2Jin Wang3Xiaochen Zhang4Xiaochen Zhang5Siliang Duan6Siliang Duan7Weiming Liang8The First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaMedicine College, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaMedicine College, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaThe First Affiliated Hospital of Guangxi University of Science and Technology, Guangxi University of Science and Technology, Liuzhou, Guangxi, ChinaIntroductionThis meta-analysis aimed to evaluate the efficacy and safety of Lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors (PD-1 inhibitors) in the treatment of intermediate or advanced hepatocellular carcinoma (HCC).Materials and MethodsFour databases (Pubmed, Embase, Web of Science, and Cochrane Library) were searched for studies comparing lenvatinib plus transarterial chemoembolization with PD-1 inhibitors (TACE-L-P) versus Lenvatinib plus transarterial chemoembolization (TACE-L) for intermediate or advanced HCC. Meta-analyses were conducted for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and Grade ≥ 3 treatment-related adverse events (Grade ≥ 3 AEs).ResultsThe meta-analysis comprised 19 retrospective cohort studies, including of 2002 patients diagnosed with intermediate or advanced HCC. In this cohort, 1011 individuals were administered TACE-L-P, while 991 patients received TACE-L. In comparison to TACE-L, TACE-L-P demonstrated a superior ORR [odds ratio (OR) = 2.38, 95% confidence interval (CI) 1.98 ~ 2.87, P < 0.00001] and DCR (OR = 3.22, 95% CI, 2.32 ~ 4.45, P < 0.00001). TACE-L-P showed superior efficacy compared to TACE-L regarding PFS (HR: 0.56, 95%CI 0.50 to 0.62, P<0.0001) and OS (HR: 0.70, 95%CI 0.60 to 0.80, P<0.0001). Regarding safety, the incidence of Grade ≥ 3 AEs was more prevalent in the TACE-L-P group compared to the TACE-L group (OR=1.58, 95% CI: 1.27 ~ 1.97, P<0.0001).ConclusionsThe present meta-analysis present a comparison of the efficacy and safety of TACE-L-P against TACE-L for intermediate or advanced HCC. TACE-L-P enhanced ORR, DCR, PFS, and OS relative to TACE-L. Furthermore, the improved efficacy of TACE-L-P was correlated with a rise in the incidence of Grade ≥ 3 AEs.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024590414, identifier CRD42024590414.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1586914/fullhepatocellular carcinomalenvatinibPD-1 inhibitortransarterial chemoembolizationprogression-free survivaloverall survival |
| spellingShingle | Yongfa Lei Xiaotian Liang Hua Zhu Jin Wang Xiaochen Zhang Xiaochen Zhang Siliang Duan Siliang Duan Weiming Liang Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis Frontiers in Immunology hepatocellular carcinoma lenvatinib PD-1 inhibitor transarterial chemoembolization progression-free survival overall survival |
| title | Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis |
| title_full | Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis |
| title_short | Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis |
| title_sort | efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death 1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma a systematic review and meta analysis |
| topic | hepatocellular carcinoma lenvatinib PD-1 inhibitor transarterial chemoembolization progression-free survival overall survival |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1586914/full |
| work_keys_str_mv | AT yongfalei efficacyandsafetyoflenvatinibplustransarterialchemoembolizationwithorwithoutprogrammeddeath1inhibitorsinthetreatmentofintermediateoradvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis AT xiaotianliang efficacyandsafetyoflenvatinibplustransarterialchemoembolizationwithorwithoutprogrammeddeath1inhibitorsinthetreatmentofintermediateoradvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis AT huazhu efficacyandsafetyoflenvatinibplustransarterialchemoembolizationwithorwithoutprogrammeddeath1inhibitorsinthetreatmentofintermediateoradvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis AT jinwang efficacyandsafetyoflenvatinibplustransarterialchemoembolizationwithorwithoutprogrammeddeath1inhibitorsinthetreatmentofintermediateoradvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis AT xiaochenzhang efficacyandsafetyoflenvatinibplustransarterialchemoembolizationwithorwithoutprogrammeddeath1inhibitorsinthetreatmentofintermediateoradvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis AT xiaochenzhang efficacyandsafetyoflenvatinibplustransarterialchemoembolizationwithorwithoutprogrammeddeath1inhibitorsinthetreatmentofintermediateoradvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis AT siliangduan efficacyandsafetyoflenvatinibplustransarterialchemoembolizationwithorwithoutprogrammeddeath1inhibitorsinthetreatmentofintermediateoradvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis AT siliangduan efficacyandsafetyoflenvatinibplustransarterialchemoembolizationwithorwithoutprogrammeddeath1inhibitorsinthetreatmentofintermediateoradvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis AT weimingliang efficacyandsafetyoflenvatinibplustransarterialchemoembolizationwithorwithoutprogrammeddeath1inhibitorsinthetreatmentofintermediateoradvancedhepatocellularcarcinomaasystematicreviewandmetaanalysis |